Fortress Biotech (FBIO) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fortress Biotech (FBIO) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 28.2% versus a loss of 57.5%. Over five years, ONCY leads with a -75.5% price change compared with -95.5% for FBIO. Oncolytics Biotech is the larger company by market cap ($71.4 million vs $69.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | ONCY |
|---|---|---|
| Share price | $2.09 | $0.5444 |
| Market cap | $69.70M | $71.38M |
| 1-day change | +2.45% | -8.63% |
| YTD return | -42.90% | -37.43% |
| 1-year return | -28.18% | -57.47% |
| 5-year return | -95.48% | -75.48% |
| P/E ratio (TTM) | 0.76 | — |
| EPS (TTM) | $2.76 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.53 | $1.32 |
| 52-week low | $2.00 | $0.54 |
| Distance from 52-week high | -53.86% | -58.76% |
| Analyst consensus | none | buy |
| Avg. price target upside | +139.23% | +662.31% |
| Average volume | 495.05K | 1.08M |
| Shares outstanding | 33.35M | 131.12M |
| Employees | 78 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FBIO has outperformed ONCY by 29.3 percentage points over the past year.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Healthcare · Biotechnology · 78 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Healthcare · Biotechnology · 29 employees
FBIO vs ONCY FAQ
Which is bigger, Fortress Biotech or Oncolytics Biotech?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $71.38M compared with $69.70M for Fortress Biotech (FBIO).
Which stock has performed better over the past year, FBIO or ONCY?
FBIO returned -28.18% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.